The patient received a full face treatment on (b)(6) 2018.During the treatment there were no errors and nothing out of the ordinary.On (b)(6) 2018 the patient noticed erythema residual scabbing.Additional information has been requested, yet not received, regarding the patient's current status.
|
It was reported a patient experienced erythema and residual scabbing on the face post fraxel treatment.The customer reported no system errors or anything out of the ordinary occurring during treatment.System has software safeguards (such as a power on self-test) that will trigger error/event codes should system be outside of acceptable limits.Customer can also utilize the burn paper to confirm system laser is providing correct pattern/coverage.Customer did not perform a burn paper test and no review could be performed.According to fraxel user manual (p009220-02 rev.A), prolonged redness and blistering are known possible complication of fraxel treatment.Mild-moderate transient erythema is an expected response.However, if erythema is severe or persists significantly longer than expected, re-treatment should be avoided until the condition resolves.Reaction may vary on a patient-by-patient basis.Blistering or burns may develop over the treated areas.A review of the manufacturing records showed all requirements were met.The customer reported no system errors or anything out of the ordinary during treatment.Based on the available information, prolonged redness and blistering are known possible complication of fraxel treatment.Trending will be performed to monitor this issue.No further action is required at this time.
|